Biorasi Recognized on Inc. 5000 List of Fastest-Growing Private Companies
MIAMI: Biorasi, a leading global full-service contract research organization (CRO), has been named on the Inc. 5000 list of the fastest-growing private companies for 2020. This prestigious ranking from Inc. magazine distinguishes Biorasi as an industry leader in the health services and clinical trial management industries.
“Biorasi is honored to be included in the Inc. 5000 again this year,” said Scott Nenninger, CFO at Biorasi. “As a CRO leader recognized for executing fast and agile clinical trials, we have differentiated ourselves in the marketplace and are being rewarded with exceptional growth. The value creation of our speed and agility for our clients has only accelerated with the challenges of the COVID-19 pandemic.”
A Legacy of Leadership
Biorasi has been recognized by Inc. previously, taking a coveted spot in the top 500 fastest-growing private companies in 2015. This year’s ranking of No. 2,189 is yet another indication of the company’s continued viability and solidifies its presence as an industry leader with a three-year growth of 192 percent.
Established in 2002, Biorasi earned its place in the CRO industry as a tech-savvy and reliable partner for clinical trial rescue – providing early intervention for faltering clinical studies and maintaining trial milestones and timelines. Today, the company maximizes speed and agility by leveraging their core competencies of innovative project management, clinical expertise, and real-time digital technology solutions designed to improve speed-to-market for pharmaceuticals and medical devices.
“Biorasi is proud of what this award implies about the way our clients value what we do. Our growth is a byproduct of our laser-focus on trial execution and on delighting our clients,” notes Chris O’Brien, CEO at Biorasi. “Our goals for the future are unchanged: leveraging our expertise and breakthrough technologies to deliver fast and reliable answers for our sponsors, keeping our finger on the pulse of industry trends, and expediting life-saving treatments for patients.”
